SCHEMBL22845202

SCHEMBL22845202

O=C(NCc1ccccc1)c1cnn2c3c(c(=O)n(-c4ccccc4)c12)CCN(C(=O)c1ccc(Cl)c(Cl)c1)C3

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.40
HTT P42858 3/20 0.40
MEN1 O00255 1/20 0.40
RECQL P46063 1/20 0.40
KMT2A Q03164 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
PRKAA2 P54646 2/20 0.39
ALDH1A1 P00352 3/20 0.38
MAPT P10636 2/20 0.38
GAA P10253 1/20 0.38
HPGD P15428 2/20 0.37
KDM4E B2RXH2 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
RPA1 P27694 1/20 0.36
POLB P06746 1/20 0.36
MAPK11 Q15759 1/20 0.36
MAPK14 Q16539 1/20 0.36
EPHX2 P34913 1/20 0.36
TACR3 P29371 1/20 0.36
PLAT P00750 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24173921 0.93 DHODH (0.42) LMNAMEN1KMT2AALDH1A1MAPT
SCHEMBL22845293 0.90 HPGD (0.40) LMNAHTTSMN1; SMN2ALDH1A1MAPT
SCHEMBL22845368 0.88 PREP (0.40) LMNAHTTMEN1RECQLKMT2A
SCHEMBL22845213 0.88 MTHFD2 (0.43) LMNAHTTMEN1KMT2ASMN1; SMN2
SCHEMBL22845214 0.87 LMNA (0.37) LMNAHTTMEN1KMT2ASMN1; SMN2
SCHEMBL22845286 0.85 LMNA (0.40) LMNAHTTMEN1KMT2ASMN1; SMN2
SCHEMBL22845409 0.84 TSHR (0.40) LMNASMN1; SMN2ALDH1A1MAPTGAA
SCHEMBL22845369 0.84 NPY2R (0.39) LMNAHTTSMN1; SMN2ALDH1A1MAPT
SCHEMBL22845379 0.84 PREP (0.36) LMNAHTTMEN1RECQLKMT2A
SCHEMBL22845341 0.84 PREP (0.37) LMNAHTTMEN1RECQLKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220000874-A1 TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2022-01-06 US disclosed
US-11136321-B2 Tricyclic compounds ALIGOS THERAPEUTICS, INC. (US) 2021-10-05 US disclosed
US-20200407361-A1 TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2020-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220000874-A1 TRICYCLIC COMPOUNDS SLC10A1, PKD1, CEL LMNA 1680/4885HTT 311/4885MEN1 274/4885
US-11136321-B2 Tricyclic compounds SLC10A1, PKD1, CEL LMNA 1680/4885HTT 311/4885MEN1 274/4885
US-20200407361-A1 TRICYCLIC COMPOUNDS SLC10A1, PKD1, CEL LMNA 1680/4885HTT 311/4885MEN1 274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.